The European Union's chief executive criticised Anglo-Swedish vaccine-maker AstraZeneca on Wednesday, accusing the embattled pharmaceutical company of delaying Europe's coronavirus vaccination campaign and warning that the EU is weighing export bans to ensure supplies.
AstraZeneca has unfortunately under-produced and under-delivered, and this painfully, of course, reduced the speed of the vaccination campaign, European Commission President Ursula von der Leyen told reporters.
Von der Leyen said the company originally pledged to deliver 90 million doses of its shot in the first three months of 2021, but later said it could only provide 40 million, then more recently only 30 million.
Beyond criticism for its slow deliveries, notably in Europe, AstraZeneca also has had to deal with reports of dangerous blood clots in some recipients of its shot, although the company and international regulators say there is no evidence the vaccine is to blame. Several countries, including Germany, France, Italy and Spain, have suspended its use.
The EU's drug regulator insisted Tuesday that there is no indication it does so, and von der Leyen said Wednesday that I trust AstraZeneca, I trust the vaccines.
AstraZeneca's formula is one of three vaccines in use on the continent. But the escalating concern is another setback for the EU's vaccination drive, which has been plagued by shortages and other hurdles and is lagging well behind the campaigns in Britain and the US.
For the second quarter of 2021, van der Leyen said, AstraZeneca will only deliver 70 million doses, less than half of the 180 million it was contractually obliged to deliver.
Two production sites in the UK figure in the EU's advance purchasing agreement drawn up with AstraZeneca, she said, adding: We're still waiting for doses to come from the UK," she said.
Von der Leyen also noted the EU has exported around 41 million vaccine doses to other countries. But open roads run in both directions, and this is why we need to ensure that there is reciprocity and proportionality, she said.
If the situation does not change, we will have to reflect on how to make exports to vaccine producing countries dependent on their level of openness, she added, without naming any country.
She said the EU still aims to vaccinate 70% of all adults by September.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)